{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Actinic keratosis",
      "field cancerization",
      "ingenol disoxate",
      "ingenol mebutate"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "28264612",
  "DateCompleted": {
    "Year": "2018",
    "Month": "02",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2017",
        "Month": "04",
        "Day": "04"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1080/09546634.2017.1303568"
    ],
    "Journal": {
      "ISSN": "1471-1753",
      "JournalIssue": {
        "Volume": "28",
        "Issue": "7",
        "PubDate": {
          "Year": "2017",
          "Month": "Nov"
        }
      },
      "Title": "The Journal of dermatological treatment",
      "ISOAbbreviation": "J Dermatolog Treat"
    },
    "ArticleTitle": "A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 43204) for field treatment of actinic keratosis on full face or 250\u2009cm<sup>2</sup> on the chest.",
    "Pagination": {
      "StartPage": "652",
      "EndPage": "658",
      "MedlinePgn": "652-658"
    },
    "Abstract": {
      "AbstractText": [
        "Actinic keratoses (AKs) may progress to squamous cell carcinoma and can occur in cancerized fields as sub-clinical and clinically visible lesions. Ingenol disoxate gel is a topical field therapy for AK. This Phase I/II trial aimed to assess the safety and efficacy of ingenol disoxate on full face or chest in patients with AKs.",
        "Part 1 was a phase-I, open-label, dose-escalation trial investigating the maximum tolerated dose of ingenol disoxate. Part 2 was a phase-II, randomized, double-blind, vehicle-controlled trial; patients were randomized 1:1:1:1 to ingenol disoxate 0.018%, 0.012%, 0.006% gel or vehicle for 2 consecutive days.",
        "Reduction in AK count from baseline at Week 8 was significantly higher than with vehicle for all doses of ingenol disoxate gel (0.018%, 79.0%; 0.012%, 73.4%; 0.006%, 69.7%; vehicle; 42.3%; p\u2009<\u2009.001). Local skin responses peaked at Day 3 for all doses, rapidly declined, and reached mild levels at Week 2. Most adverse events were mild or moderate in intensity, and were most commonly application site pain/pruritus.",
        "Ingenol disoxate gel is efficacious and well tolerated as field treatment for AKs on the full face or chest. Clinical Trial No.: NCT01922050."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "a Department of Dermatology , Hop G. L. Dumont , Moncton , NB , Canada."
          }
        ],
        "LastName": "Bourcier",
        "ForeName": "Marc",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "b Department of Dermatology , Henry Ford Hospital , Detroit , MI , USA."
          }
        ],
        "LastName": "Stein Gold",
        "ForeName": "Linda",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "c Guenther Research Inc. , London , ON , Canada."
          }
        ],
        "LastName": "Guenther",
        "ForeName": "Lyn",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "d LEO Pharma A/S , Ballerup , Denmark."
          }
        ],
        "LastName": "Andreassen",
        "ForeName": "Camilla M",
        "Initials": "CM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "d LEO Pharma A/S , Ballerup , Denmark."
          }
        ],
        "LastName": "Selmer",
        "ForeName": "Johan",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "e Department of Dermatology , Icahn School of Medicine at Mount Sinai , New York , NY , USA."
          }
        ],
        "LastName": "Goldenberg",
        "ForeName": "Gary",
        "Initials": "G"
      }
    ],
    "DataBankList": [
      {
        "DataBankName": "ClinicalTrials.gov",
        "AccessionNumberList": [
          "NCT01922050"
        ]
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial, Phase I",
      "Clinical Trial, Phase II",
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "J Dermatolog Treat",
    "NlmUniqueID": "8918133",
    "ISSNLinking": "0954-6634"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Diterpenes"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "LEO 43204"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged, 80 and over"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Diterpenes"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Face"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Keratosis, Actinic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Pain"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Placebo Effect"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Pruritus"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Thorax"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}